Breaking Canadian GLP-1 news
GLP-1 News — Page 8
Drug approvals, price changes, generic timelines, and clinical trial results affecting GLP-1 medication costs in Canada.
Find my best option
Answer a few quick questions — get your cheapest path to a GLP-1 prescription, free.
Health Canada Approves New Novo Nordisk Semaglutide Brand Names
Health Canada approves new brand names for Novo Nordisk semaglutide products as company prepares for generic competition entering Canadian market.
Aspen Pharmacare Targets Q3 2026 Generic Semaglutide Launch
South African pharmaceutical giant Aspen Pharmacare plans to enter Canadian market with generic semaglutide by third quarter 2026, using Canada as reference.
WHO Conditionally Recommends GLP-1 Therapies for Obesity Treatment
World Health Organization issues conditional recommendation for GLP-1 therapies in obesity treatment, marking significant shift in global health policy approach.
Generic GLP-1 Medications Expected on Canadian Shelves This Summer
National Post reports generic semaglutide products could reach Canadian pharmacy shelves by summer 2026 as Health Canada reviews nine applications.
Study: Generic Semaglutide Production Costs Just $3 Monthly
New research reveals generic semaglutide manufacturing costs could drop to $3 per month in Canada, representing massive savings from current $400 prices.
Health Canada Eyes Summer 2026 Generic Semaglutide Approvals
Radio-Canada International reports Health Canada reviewing nine generic semaglutide submissions with summer 2026 approval timeline expectations for Canadian patients.
Canada's Drug Agency to Decide Mounjaro Coverage Within Weeks
Canada's Drug Agency expected to announce public plan coverage decision for Eli Lilly's Mounjaro within weeks, affecting provincial formulary access.
Alberta Blue Cross Reports Second Wave GLP-1 Innovation for 2026
Alberta Blue Cross drug pipeline report highlights improved formulations and expanded applications driving continued GLP-1 therapy growth in 2026.
Novo Nordisk Launches $199 Introductory Price for Low-Dose GLP-1s
Novo Nordisk introduces $199 monthly pricing for starter doses of Wegovy and Ozempic in Canada, expanding access ahead of generic competition.
Hims & Hers Launches Canadian Operations Ahead of Generic GLP-1s
US telemedicine company Hims & Hers expands into Canada as the country prepares for generic semaglutide availability starting mid-2026.
GLP-1 Drugs Drive Major Canadian Employer Drug Plan Cost Increases
New Benefits Canada report reveals GLP-1 medications are a major driver of employer drug plan cost increases in 2026 despite expected generic approvals.
Canada's Drug Agency Estimates Wegovy Costs $5,000 Annually
Canada's Drug Agency releases official annual cost estimate of $5,000 for Wegovy based on recommended maintenance dose, providing new government costing data.
Generic Semaglutide Could Cut Canadian Drug Costs by 65%
Benefits industry analysis projects 65% price reduction for generic semaglutide in Canada as Health Canada reviews nine applications from manufacturers.
Health Canada Adds Submission Class Data to Drug Review Tracker
Health Canada enhanced its public drug review tracker on March 20, 2026, adding submission class information to help Canadians track generic applications.
GLP-1 Drug Costs Could Drop from $400 to $15 Monthly in Canada
Current $300-400 monthly costs for Ozempic and Wegovy could fall to $15 with generic competition, representing a 96% price reduction for Canadian patients.
Generic Semaglutide Manufacturing Begins at Canadian Facilities
Canadian pharmaceutical companies have begun production of generic semaglutide at domestic manufacturing facilities ahead of regulatory approvals.
Health Canada Approves Rybelsus for Heart Disease Prevention
Health Canada expands Rybelsus approval to reduce major cardiovascular events in adults with Type 2 diabetes and heart disease risk factors.
Health Canada May Approve First Generic Semaglutide May-September
Industry sources indicate Health Canada could approve the first generic semaglutide between May and September 2026, marking a narrower timeline than previous estimates.
Dr. Reddy's, Sun Pharma Apply for Generic Semaglutide in Canada
Two major Indian pharmaceutical companies have submitted applications to Health Canada for generic semaglutide approval, joining the competitive race.
Generic Ozempic Approvals Expected Spring 2026 in Canada
Industry experts predict Health Canada will approve first generic semaglutide applications by spring 2026, with multiple approvals expected by year-end.
Looking for current pharmacy prices?
Compare GLP-1 prices across Canada